One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America by Podlekareva, DN et al.
Page 1 of 23 
 
Title: One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid- 
susceptible tuberculosis in Eastern Europe, Western Europe and Latin America. 
The TB:HIV Study writing Group*¶ 
*D.N. Podlekareva1, 2, A. Schultze3, A. Panteleev4, A.M. Skrahina5, J.M. Miro6,  A. Rakhmanova7,†, H. Furrer8, 
R.F Miller9, A.M. W. Efsen1, M.H. Losso10, J. Toibaro10, A. Vassilenko11, E. Girardi12, J.D. Lundgren1, A. 
Mocroft3, F.A. Post13, O. Kirk1, and the TB:HIV study in EuroCoord# 
Affiliations: 
1 CHIP, Department of Infectious Diseases and Rheumatology, Finsencentret, Rigshospitalet, University of 
Copenhagen, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark (Daria N. PODLEKAREVA (MD), Anne Marie 
Werlinrud EFSEN (MD), Jens D. LUNDGREN (DMSc), Ole KIRK (DMSc)).  
2Department of Pulmonary and Infectious Diseases, Nordsjaelland Hospital, Hilleroed, Dyrehavevej 29, Hilleroed, 
Denmark (Daria N. PODLEKAREVA (MD) 
3Department of Infection and Population Health, University College London Medical School, Rowland Hill Street, 
NW3 2PF, London, UK ((Anna SCHULTZE (MSc), Amanda MOCROFT (Professor)).  
4Department of HIV/TB, TB hospital 2, Ushinskogo str 39/1 – 122, 195267 St. Petersburg, Russia (Alexander 
PANTELEEV (DMSc)) 
5Republican Research and Practical Centre for Pulmonology and TB, Dolginovski trakt 157, 220053 Minsk, Belarus 
(Alena M. SKRAHINA (DMSc)) 
6Infectious Diseases Service, Hospital Clinic – IDIBAPS. University of Barcelona, Villarroel, 170, 08036 Barcelona, 
Spain (Jose M. MIRO (PhD)) 
7Botkin Infectious Disease Hospital, Mirgorodskaya str 3, 191167 St. Petersburg, Russia (Aza RAKHMANOVA 
(DMSc)) †Deceased 
8Department of Infectious Diseases, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland 
(Hansjakob FURRER (Professor)) 
9Centre for Sexual Health and HIV Research, Mortimer Market Centre, University College London, London WC1E 
6JB, UK (Robert F. MILLER (Professor)) 
10Department of immunocompromised, Hospital J.M. Ramos Mejia, Pabellón de Cliníca, 2do Piso, CP 1221 
Buenos Aires, Argentina (Marcelo H. LOSSO (MD), Javier TOIBARO (MD)) 
11Belarusian State Medical University, Dzerzhinski Ave., 83, Minsk, Republic of Belarus, 220116. Department of 
Infectious Diseases, City Clinical Hospital of infectious Diseases, 220002, Minsk, str. Kropotkin, 76 (Anna VASILENKO 
(MD)) 
12Department of Infectious Diseases INMI "L. Spallanzani", Ospedale L Spallanzani, Via Portuense, 292, 00149 
Rome, Italy (Enrico GIRARDI (MD)) 
13Department of Sexual Health, Caldecot Centre, King's College Hospital, Bessemer Road, London SE5 9RS, UK 
(Frank A. POST (MD)) 
Page 2 of 23 
 
¶Contribution of each member of the HIV/TB study writing group is described at the end of the manuscript 
#A full list of the TB:HIV Study Group investigators can be found in the acknowledgement section 
 
Corresponding author: 
Daria Podlekareva MD, PhD 
Rigshospitalet, University of Copenhagen  
CHIP, Department of Infectious Diseases, Section 2100 (CHIP) 
Blegdamsvej 9 
DK-2100 Copenhagen Ø, Denmark 
Phone: + 45 35 45 57 57 
Fax: +45 35 45 57 58 
Mail: daria.podlekareva@regionh.dk/  daria.podlekareva@gmail.com 
Web: www.regionh.dk/  www.chip.dk  
 
Short title: Mortality in HIV patients with susceptible tuberculosis  
Key words: tuberculosis, HIV, treatment, drug -susceptibility testing, death, Eastern Europe, Western 
Europe, Latin America, TB:HIV study  
Word count:  
Abstract: 247 
Article: 2920 
 
Conference presentation 
Results from this study were presented at the 15th European AIDS Conference (EACS), October 21-24, 
2015, Barcelona, Spain. Abstract PS2/2. 
Page 3 of 23 
 
Abstract (word count 247) 
Objectives: The high mortality among HIV/tuberculosis (TB) co-infected patients in Eastern Europe (EE) is 
partly explained by the high prevalence of drug-resistant TB. It remains unclear whether outcomes of 
HIV/TB patients with rifampicin/isoniazid-susceptible TB in EE differ from those in Western Europe (WE) or 
Latin America (LA). 
Methods: One-year mortality of HIV-positive patients with rifampicin/isoniazid-susceptible TB in EE, WE 
and LA was analysed and compared in a prospective observational cohort study. Factors associated with 
death were analysed using Cox regression models  
Results: 341 patients were included (EE 127, WE 165, LA 49). Proportions of patients with disseminated TB 
(50%, 58%, 59%) and initiating rifampicin+isoniazid+pyrazinamide-based treatment (93%, 94%, 94%) were 
similar in EE, WE and LA respectively, while receipt of antiretroviral therapy (ART) at baseline and after 12 
months was lower in EE (17%, 39%, 39%, and 69%, 94%, 89%). The one-year probability of death was 16% 
(95%CI 11%-24%) in EE, vs. 4% (2%-9%) in WE and 9% (3%-21%) in LA; p<0.0001. After adjustment for 
injecting drug use (IDU), CD4-cell count and receipt of ART, those residing in EE were at nearly 3-fold 
increased risk of death compared to those in WE/LA (aHR 2.79 (1.15-6.76); p=0.023).  
Conclusions: Despite comparable use of recommended anti-TB treatment, mortality of patients with 
rifampicin/isoniazid-susceptible tuberculosis remained higher in EE when compared with WE/LA. The high 
mortality in EE was only partially explained by IDU, use of ART and  CD4 cell count. These results call for 
improvement of care for TB/HIV patients in EE. 
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Introduction 
Currently, tuberculosis (TB) is a public health emergency in Eastern Europe (EE). [1] The incidence of TB 
among HIV-infected populations is rapidly increasing in this region, and the situation is complicated by an 
increase in the prevalence of multi-drug resistant (MDR) TB. [2-4] We have previously documented an 
excess mortality rate among TB/HIV patients in EE, which can only partially be explained by the high 
prevalence of MDR-TB, suboptimal access to drug susceptibility testing (DST), and as a consequence, use of 
inadequate anti-TB treatment regimens. [5]  
One of the risk factors for development of MDR-TB is previous (inadequate) TB treatment which permitted 
drug resistance to be selected or amplified. [6, 7] By contrast, high rates of MDR-TB among new TB cases 
without a history of prior TB, as well data from modelling studies, suggest that transmission of drug 
resistant TB plays an important role in the ongoing epidemic of MDR-TB in EE. [8, 9] From a patient as well 
as from a public health perspective it is therefore important to appropriately treat drug sensitive (DS) TB, 
ensuring that patients are cured and their infection is eliminated. This strategy would help prevent the 
development and potential further spread of MDR-TB.  Treatment of MDR-TB is complex due to the drug 
burden, prolonged treatment duration, adverse effects, high cost, and the limited availability of many drugs 
in low- and middle-income regions. [10-12] Besides, the overall success rate of treating MDR-TB is only 
around 50%. [13] By contrast, treatment of drug susceptible (DS)-TB is inexpensive, requires fewer clinical 
(nurse- and doctor-led) resources, and first-line drugs are widely available in resource-limited settings. [14, 
15] Provided that recommendations for treatment of DS-TB are used and adhered to both by clinicians and 
patients, successful TB outcome can be achieved in a majority of patients, which is according to World 
Health Organisation (WHO) 2015 standards. [16]  
In the presence of HIV coinfection, it is also of paramount importance to adequately treat the underlying 
HIV infection. [17] Timely initiation of antiretroviral therapy (ART) improves immune function and hence 
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prevents of active TB disease, or in the settings of already developed TB, significantly improves outcome. 
[18, 19] 
We hypothesised that mortality rates among TB/HIV patients with DS-TB in EE would be comparable to 
those in Western Europe (WE) and Latin America (LA). The present analysis aimed to assess and compare 
mortality rates of HIV patients with drug susceptible TB across regions and identify risk factors associated 
with mortality. Further, we aimed to describe management of HIV co-infection in patients with DS-TB. 
Methods 
The current analyses were conducted within the prospective TB:HIV cohort study. Details of the study 
design and methodology have been published elsewhere. [20] Briefly, HIV-positive persons aged 16 years 
or older who were diagnosed with TB between January 2011 and December 2013 in 62 participating HIV 
and TB clinics in 19 countries from EE, WE or LA 1 were enrolled and followed-up for 24 months. 
Demographic, clinical and laboratory information was prospectively collected on case report forms at TB 
diagnosis, 6, 12 and 24 months thereafter. The study received approval from Ethics Committees in all 
countries as per local regulations. 
The current analysis is limited to 12 months of follow-up and the database was closed for analysis in May 
2015, when all 12 months follow-up data were collected. Baseline was defined as the date when anti-TB 
treatment was initiated. Drug susceptibility tests (DST), obtained within 4 weeks of baseline were used to 
confirm mycobacterial susceptibility to rifampicin and isoniazid. Patients without a DST and those with 
rifampicin- and/or isoniazid-resistant TB were excluded from the current analyses. Patients were stratified 
by their region of residence. Descriptive statistics were used for baseline characteristics. Study definitions 
in terms of certainty of TB diagnosis, clinical presentation of TB disease, TB treatment regimens, ART 
                                                          
1 Eastern Europe (EE) (21 clinics in Belarus, Estonia, Georgia, Latvia, Lithuania, Poland, Romania, Ukraine, Russia), 
Western Europe (WE) (28 clinics in Belgium, Denmark, France, Italy, Spain, Switzerland, United Kingdom), and Latin 
America (LA) (13 clinics in Argentina, Chile, and Mexico). 
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regimens and region of residence have previously been published and re-used in the current analysis for 
consistency. [5] 
Treatment of underlying HIV-infection was analysed by calculating proportion of patients receiving 
antiretroviral therapy (ART) at baseline, 3, 6, 9 and 12 months, and by assessing immuno-virological status 
of the cohort at the same time-points. Response to ART was assessed among those who started ART at or 
within 6 months after their TB diagnosis. It was done by calculating proportion of patients with HIV-RNA 
<500 copies/ml in the time period 2-7 months after starting ART out of those alive and still under follow-up. 
ART was defined as a combination of at least three antiretroviral drugs of any class. 
Mortality was compared using Kaplan-Meier survival analysis in which patients were censored at their last 
clinic visit, date of death, or after 12 months of follow-up, whichever occurred first. Risk factors for death 
were identified by Cox proportional hazard models that included region of residence, where WE and LA 
were combined due to the small numbers of deaths in these regions.  Following “a priori” defined variables 
were tested in the uni- and multivariate models:  gender, age (per 10 years increase), history of injection 
drug use (IDU: yes or no), extent of TB disease (pulmonary or disseminated), use of rifampicin, isoniazid and 
pyrazinamide in the initial anti-TB treatment regimen, baseline CD4 cell count (as a categorical variable), 
and use of ART (yes/no) as a time-updated variable. 
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Results 
Of the 1406 TB/HIV patients in the TB:HIV study, 644 (46%) had culture confirmed TB (360 of 834 enrolled 
participants in EE, 205 of 317 in WE, and 79 of 255 in LA, respectively). Of the 644 patients, 495(77%) had 
baseline DST results for both rifampicin and isoniazid available, and finally 341/495 (69%) were infected 
with Mycobacterium tuberculosis susceptible to both rifampicin and isoniazid. The regional distribution was 
EE 127, WE 165, and LA 49. These 341 patients were included in the present analyses (figure 1). 
The baseline clinical and demographic characteristics of these patients are described in table 1. Compared 
with WE and LA, patients in EE were slightly younger and a greater proportion in this region was co-infected 
with hepatitis C. The most common risk factors for TB/HIV acquisition in EE were: history of IDU, excess 
alcohol consumption, and/or imprisonment.  The proportion of patients with excess alcohol consumption 
was comparably high in LA, but not in WE. More than 90% of patients in all three regions commenced anti-
TB treatment that included rifampicin, isoniazid, and pyrazinamide.  At the time of TB diagnosis, patients 
from all regions had advanced immunodeficiency and over half presented with disseminated TB. Despite 
similar degrees of immunodeficiency and HIV RNA levels, a smaller proportion of those in EE were receiving 
ART at baseline. 
In Kaplan-Meier analyses of the duration of TB therapy, the time by which 50% of patients had stopped 
therapy was longer than the guideline-recommended six months in all 3 regions: 8.7 months (IQR 7.1-9.7) 
in EE, 9.0 (8.3-9.1) in WE and 9.8 (9.0-11.5) in LA. There was no evidence that the time to stopping TB 
treatment differed between regions (p=0.28). 
Management of HIV infection after initiation of anti-TB treatment is presented in figure 2. The use of ART 
increased over time in all three regions, but remained significantly lower in EE. The proportion of patients 
receiving ART in Eastern Europe increased from 17% to 54% during the first three months after start of anti-
TB treatment. Proportion of patients on ART in the two other regions was significantly higher at any time 
point and at 12 months 94% and 89% of patients in WE and LA respectively, were on ART compared with 
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69% in EE, p<0.001(figure 2). Despite the increase in ART uptake, the proportion of patients with 
suppressed HIV-RNA (<500 copies/ml), among those who were on ART, was lower in EE compared with WE 
and LA. At 12 months after TB diagnosis, 48% of patients on ART in EE had HIV RNA<500 compared with 
86% and 71% in WE and LA, respectively, p<0.001(figure 2). 
In addition to describing ART use, HIV RNA and CD4-cell status cross-sectionally at time-points after TB 
diagnosis (Figure 2), we also looked at the response to ART following the date of ART initiation among those 
who started ART at or after TB diagnosis. This analysis showed that in the time period 3-6 months after 
starting ART, 36% of individuals still alive and under follow-up in EE compared to 85% in WE and 80% in LA 
had HIV RNA<500 copies/ml (p<0.001). 
At one year from baseline, 68 patients (54%) in EE, 117 (71%) in WE and 30 (61%) in LA had completed at 
least 6 consecutive months of anti-TB treatment, p=0.009. Seventeen patients (13%) in EE, 17 (10%) in WE, 
and 7 (14%) in LA were lost to follow up, p=0.63. Twenty (16%) deaths had occurred in EE, 7 (4%) in WE and 
4 (8%) in LA, p=0.0031. In EE TB was indicated as the underlying cause of death in 13 (70%) cases, compared 
with 2 (29%) and 1 (25%) in WE and LA, respectively. A majority (9 out of 13) of TB-related death in EE 
occurred within the first 4 months after baseline. The cumulative probability of all cause death after one 
year was 16% (95% CI 11%-24%) in EE, 4% (2%-9%) in WE and 9% (3%-21%) in LA (figure 3), and numbers 
did not allow for more detailed analysis on intra-regional variability. In the adjusted model the only 
significant risk factor for death was region of residence. Thus, treatment of rifampicin and isoniazid 
susceptible TB in EE was associated with an almost 3-fold increased risk of death compared to WE and LA 
combined (adjusted Hazard Ratio 2.79; 95% CI 1.15-6.76) (figure 4). Association of ART initiation with 
patients’ prognosis was marginally significant in the unadjusted model only. This association disappeared 
after adjustment likely due to the small numbers and limited statistical power. IDU was also a significant 
predictor of death before adjustment, however this also became non-significant after adjustment due to 
the high correlation with the region of residence (figure 4). 
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Discussion 
This study demonstrates greater mortality rate among HIV patients infected with rifampicin-and isoniazid-
susceptible TB in EE compared with WE and LA. This difference persisted after adjustment for clinical 
characteristics such as IDU, low immune status at the time of TB diagnosis, and receipt of ART during follow 
up. While mortality was similar across the regions within the first 1-2 months, patients in EE continued to 
experience high death rates throughout the first year post-TB diagnosis.  By contrast with EE, TB/HIV 
coinfected patients in LA, another middle-income region, and in WE, a high income region, experienced low 
mortality rates, reflecting high standards of TB and HIV care in the latter mentioned regions. [17, 21, 22] 
The differences in TB outcome were only partially explained by factors, related to HIV management, in 
particular use of ART and CD4 cell levels, or by other factors included in the model.  This underscores the 
fact that some other factors, probably on a higher level than individual clinics and that we were not able to 
test, play an important role in patients’ survival, as for example:  national and regional healthcare and 
social infrastructure. 
A vast majority of patients from all regions initiated their anti-TB treatment with the standard recommended regimen, 
i.e. rifampicin, isoniazid, and pyrazinamide-based, indicating that these drugs are widely available and clinicians follow 
standard recommendations for TB treatment. [14]  This is however not enough to ensure a good outcome, particularly 
in the settings of HIV coinfection. ART should be initiated as soon as possible after TB diagnosis, if a patient was not 
already receiving it. [23-25] In our study, management of HIV infection in EE was suboptimal. Even though ART 
coverage had increased with time, both usage of ART and response to ART was still much lower than in the other 
regions, inferring that ART was not properly prescribed and/or taken. By contrast, HIV management in WE was 
according to the standards; ART coverage was over 90% and nearly 90% of patients on ART achieved viral suppression. 
[26] LA showed results very close to those in WE, demonstrating that appropriate HIV care is also possible in resource-
constrained settings. In our study, initiation of ART did not play a significant role in patients’ survival after 
adjustment for other risk factors for death. However, binary adjustment for ART initiation (yes vs. no) may 
not fully reflect the impact of ART on mortality, and there are other aspects of HIV treatment that we could 
not adjust for due to the lack of data, and therefore not fully capture all aspects of HIV care. Scale up of ART 
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still remains paramount in the management of HIV infection, although it is also important to ensure that 
effective drugs are used and that adherence is maximised. In the present study the most common reason 
for not starting ART by two months after start of anti-TB treatment was patients’ refusal (data not shown), 
suggesting perhaps that patients may not fully appreciate or are not aware of the life-saving effects of ART. 
Other factors, as for example, concerns of toxicity, lack of food and/or accommodation might also play a 
role and need to be overcome.  It is therefore a major task not only for clinicians, but also for community 
and social services to educate, engage and retain patients in care. 
One of the drivers of the TB/HIV epidemic in EE is IDU, a marginalised population with poor access to and 
uptake of health services, resulting in late presentation of both HIV and TB, poor rates of TB treatment 
completion, and frequent ART interruptions.  [27] Healthcare systems in EE need to better account the 
special needs of this large patient population, considering its lifestyle and ability to accept continuous 
treatment. [27] Measures should be taken to help IDU patients to remain in care and overcome structural 
barriers, improve health literacy and minimise stigma. There is a need for a patient-centred integrated 
multidisciplinary approach, involving both HIV and TB clinicians, as well as social support and provision of 
opiate substitution therapy, which is currently poorly available. [28-31] Integration of HIV and TB services, 
although improving, is still suboptimal in EE and close collaboration of physicians from both specialities is 
limited. Healthcare infrastructure continues to be driven by a strong vertical system, not allowing for 
interdisciplinary collaboration. [12]  Community involvement and patients’ education and support services 
need to be improved as well.  
 Of note, we were not able to document any significant differences in mortality within EE in explorative 
analyses stratified by IDU status (yes vs. no), perhaps due to limited numbers, but it may also be due to 
high prevalence of risk factors such as alcohol abuse and imprisonment among non-IDU individuals. This 
highlights the need for an approach that supports vulnerable patient groups in addition to individuals who 
are IDU. Prevalence of HCV coinfection is rather high among HIV/TB patients in EE (app. 50% in our study), 
thus management of this disease should also be integrated. 
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The study has several strengths and limitations. As a prospective cohort study, our data reflect the “real 
life” situation in the participating clinics/countries in terms of data availability, such as DST, HIV-RNA, CD4 
cell count, at the same time limiting interventions and more careful study of the risk factors, associated 
with death.  Many clinics in EE do not have the infrastructure to support patients’ retention in care. 
Moreover, patients may have to attend different facilities for inpatient and outpatient treatment. Thus the 
loss to follow-up rate might be high, although major attempts have been taken to minimise it. All missing 
data were queried, all death, MDR-TB cases and at least 10% of random patients were monitored and 
guidelines on how to minimise LTFU was developed (www.cphiv.dk).  The study did not collect detailed 
data on issues of special relevance for IDU individuals, such as adherence and whether there is an ongoing 
IDU and how that influences the patients’ life.  Due to the limited statistical power, risk factors of death 
could not be studied in more detail. The fact that the multivariate model did not remove the difference 
between regions does not exclude the possibility that the variables adjusted for in this model were on the 
causal pathway. There might be an issue of residual confounding, where the quality and availability of the 
variables (e.g. HIV-related) is insufficient to capture the biological changes that truly occurred. End-stage 
liver disease due to HCV coinfection might have contributed to the excess mortality in EE. However, we 
were not able to explore this further due to the statistical power limitations. Detailed analysis of causes of 
death and contributing factors is currently under development. Finally, there may be a general lower life 
expectancy in EE due to differences in socio-economic status, lifestyle, diets etc. This is, however, difficult 
to address in a clinical study and further research is needed. 
 
 
 
Conclusion 
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In conclusion, this study documents an unacceptable high mortality among HIV-positive patients with drug-
susceptible TB in EE despite widespread use of World Health Organization recommended anti-TB treatment 
regimens as initial therapy. Management of HIV infection was suboptimal in this region, but did not fully 
explain the high mortality. Healthcare provision for the TB/HIV population in EE needs to be urgently 
reviewed and improved. This requires a high level of political commitment both locally and globally, and 
may be achieved by improving collaboration between TB and HIV clinicians, as well as strengthening the 
existing healthcare infrastructure.   
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Figure 1. Flow chart of TB:HIV Study patients with rifampicin- and isoniazid- susceptible tuberculosis 
included in the analyses  
 
 
 
Eastern Europe (EE): Belarus, Estonia, Georgia, Latvia, Lithuania, Poland, Romania, Ukraine, Russia; Western 
Europe (WE): Belgium, Denmark, France, Italy, Spain, Switzerland, United Kingdom; Latin America (LA): 
Argentina, Chile, and Mexico 
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Table 1. Baseline demographic and clinical characteristics of 341 HIV patients with rifampicin- and isoniazid-susceptible tuberculosis 
    Eastern Europe N(%) Western Europe N(%) Latin America N(%) P 
Total   127 165 49  
Gender Male 98 (77.2) 109 (66.1) 36 (73.5) 0.108 
Age Years, Median (IQR) 36.5 (30.9 - 42.6) 38.8 (33.0 - 46.2) 38.2 (29.2 - 44.8) 0.037 
Weight Kg, Median (IQR) 58.0 (50.0 - 66.0) 60.0 (54.0 - 68.0) 55.0 (45.5 - 65.5) 0.225 
TB/HIV Risk Factors Ever Injecting drug use, N (%) 76 (60.3) 31 (18.8) 8 (16.3) <.001 
  History of imprisonment, N (%) 16 (12.6) 5 (3.0) 4 (8.2) 0.008 
  History of excess alcohol 
consumption, N (%) 
27 (21.3) 20 (12.1) 13 (26.5) 0.026 
Laboratory Markers Haemoglobin (g/dl), median 
(IQR)* 
11 (9 - 13) 11 (9 - 12) 11 (10 - 13) 0.158 
  Albumin (g/dl), median (IQR)# 29 (24 - 33) 30 (25 - 34) 26 (22 - 33) 0.484 
 TB Disease Disseminated, N (%) 64 (50.4) 95 (57.6) 29 (59.2) 0.39 
TB Treatment RHZ-based, N (%) 118 (92.9) 155 (93.9) 46 (93.9) 0.935 
   RHZ+E, N (%) 98 (83.1) 128 (82.6) 43 (93.5) 0.181 
   RHZ+S, N (%) 1 (0.8)   0.426 
   RHZ+ES, N (%) 10 (8.5) 3 (1.9) 1 (2.2) 0.024 
Hepatitis C@ Ever, N (%) 61 (48.0) 27 (16.4) 6 (12.2) <0.001 
HIV Status      
Antiretroviral therapy Yes. N (%) 21 (16.5) 64 (38.8) 19 (38.8) <0.001  
CD4 cell count, mm3/ml1 Median (IQR) 103.5 (35.0 - 258.0) 123.0 (35.0 - 280.0) 78.0 (28.0 - 218.0) 0.31 
HIV RNA, log10 copies/ml2 Median (IQR) 5.2 (4.3 - 5.7) 5.0 (2.9 - 5.7) 4.7 (2.5 - 5.6) 0.289 
 
Eastern Europe (Belarus, Estonia, Georgia, Latvia, Lithuania, Poland, Romania, Ukraine, Russia); Western  Europe (Belgium, Denmark, France, Italy, Spain, 
Switzerland, United Kingdom); Latin America (Argentina, Chile, and Mexico) 
*Data for haemoglobin available for 98 (77) patients in EE, 146 (88) in WE, and 41 (84) in LA 
#Data for albumin available for 38 (30) patients in EE, 113 (68) in WE, and 26 (53) in LA 
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@Ever tested positive for hepatitis C antibodies or hepatitis C RNA. Data for hepatitis C available for 91 (72) patients in EE, 121 (73) in WE, and 36 (73) in LA. 
Missing data are included in the denominator.  
1Baseline CD4 cell count was available for 102 (80), 162 (98) and 43 (88) patients in EE, WE, and LA 
2Baseline HIV RNA data were available for 68 (54), 157 (95) and 40 (82) patients in EE, WE, and LA 
R = Rifampicin; H = Isoniazid; Z = Pyrazinamide; E = Ethambutol; S = Streptomycin  
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Figure 2: Use of antiretroviral therapy (ART), HIV-RNA and CD4-cell count status in 341 HIV-patients with drug-susceptible tuberculosis during 12 months after 
initiation of anti-TB therapy 
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Figure 3. Probability of death among 341 HIV patients with rifampicin- and isoniazid-susceptible tuberculosis 
according to their region of residence   
 
 
 
 
 
 
Number of deaths: 20 in EE, 7 in WE and 4 in LA. 
EE: Eastern Europe (Belarus, Estonia, Georgia, Latvia, Lithuania, Poland, Romania, Ukraine, Russia); WE: 
Western Europe (Belgium, Denmark, France, Italy, Spain, Switzerland, United Kingdom); LA: Latin America 
(Argentina, Chile, and Mexico) 
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Figure 4. Cox proportional hazard model of factors associated with death in 341 HIV patients with 
rifampicin- and isoniazid-susceptible tuberculosis 
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*ART was included as a time updated variable 
 
 
Number of deaths = 31: 20 in Eastern Europe, 7 in Western Europe and 4 in Latin America. 
EE: Eastern Europe (Belarus, Estonia, Georgia, Latvia, Lithuania, Poland, Romania, Ukraine, Russia); WE: 
Western Europe (Belgium, Denmark, France, Italy, Spain, Switzerland, United Kingdom); LA: Latin America 
(Argentina, Chile, and Mexico) 
IDU, injecting drug use; ART, antiretroviral therapy; CD4 cell count measurement (cells/mm3) 
HR, hazard ratio; CI, confidence interval;  
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